(Washington, DC)— The Pharmaceutical Care Management Association (PCMA) issued the following statement today regarding various comparative effectiveness proposals that are being debated in Congress:

“PCMA believes comparing the clinical effectiveness of competing drug therapies is an important tool in promoting value-based purchasing. Pharmacy benefit managers have led the way with Pharmacy & Therapeutics (P&T) committees and a wide range of proven utilization tools—including multi-tier formularies and step therapy—to ensure patients have access to cost-effective and clinically proven prescription drugs.

“PCMA urges policy makers to explore collaborative opportunities in the public and private arenas where comparative effectiveness can successfully be implemented.”

###

PCMA is the national association representing America’s pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.

Contact Information:
Charles Coté 202-207-3605